{
    "clinical_study": {
        "@rank": "77128", 
        "arm_group": [
            {
                "arm_group_label": "Dexamethasone-implant (Group 1)", 
                "arm_group_type": "Active Comparator", 
                "description": "Group 1 included 38 patients (22 with CRVO and 16 with BRVO) and was treated with a dexamethasone-implant injection from the beginning."
            }, 
            {
                "arm_group_label": "Bevacizumab/Dexamethasone-implant (Group 2)", 
                "arm_group_type": "Active Comparator", 
                "description": "Group 2 included 26 patients (14 CRVO, 12 BRVO) and was treated with three consecutive injections of bevacizumab at a monthly interval, followed by a dexamethasone-implant injection four weeks after the last bevacizumab injection."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and safety of a dexamethasone-implant alone or in combination with\n      bevacizumab. 64 eyes are prospectively investigated. Group 1 (22 CRVO and 16 BRVO) is\n      treated with dexamethasone-implant alone, Group 2 (14 CRVO 12 BRVO) with three consecutive\n      bevacizumab injections followed by a dexamethasone-implant. Recurrences are treated with\n      dexamethasone-implant only. Patients are seen preoperatively and thereafter in monthly\n      intervals. The primary endpoint was BCVA at twelve months."
        }, 
        "brief_title": "Dexamethasone-implant for the Treatment of RVO", 
        "completion_date": {
            "#text": "February 2012", 
            "@type": "Actual"
        }, 
        "condition": "Macular Edema Caused by Retinal Vein Occlusion", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema", 
                "Retinal Vein Occlusion"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: maximum duration of symptoms of four months and no known history of\n        glaucoma or corticosteroid response in the past -\n\n        Exclusion Criteria: Glaucoma, Diabetic Retinopathy, prior IVOM, Uveitis\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01767545", 
            "org_study_id": "Mayer-DEX-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Dexamethasone-implant (Group 1)", 
                    "Bevacizumab/Dexamethasone-implant (Group 2)"
                ], 
                "intervention_name": "Dexamethasone implant", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Bevacizumab/Dexamethasone-implant (Group 2)", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Bevacizumab", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Munich", 
                    "country": "Germany", 
                    "zip": "80336"
                }, 
                "name": "Dept. of Ophthalmology, LMU Munich"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Twelve Months Experience With a Dexamethasone-implant for the Treatment of Macular Edema Associated With Retinal Vein Occlusion", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The primary clinical endpoint was BCVA twelve months after the first intravitreal treatment.", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01767545"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ludwig-Maximilians - University of Munich", 
            "investigator_full_name": "Wolfgang Mayer", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Central retinal thickness", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Lens opacity", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Saftey of procedure", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Ludwig-Maximilians - University of Munich", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ludwig-Maximilians - University of Munich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2010", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}